Connecticut is currently home to 1262 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Do Probiotics Improve Recovery From Acute Constipation in Kids?
Recruiting
The purpose of this study is to evaluate the potential benefit of adding probiotics to the standard treatment for children who present to the emergency department with acute constipation. Before evaluating probiotics as a single therapy, we believe it is prudent to evaluate for added benefit first. Specifically, we seek to determine if adding probiotics decreases the length of time to normal stool frequency, decreases the number of days with abdominal pain/cramping, and improves time to normal e... Read More
Gender:
All
Ages:
Between 6 months and 8 years
Trial Updated:
02/09/2023
Locations: Connecticut Chidlren's Medical Center, Hartford, Connecticut
Conditions: Constipation
Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study
Recruiting
The objective of this phase 2 study is to investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control among patients undergoing unilateral total knee arthroplasty (TKA) to asses if perineural B-DEX-MPA will result in superior analgesia efficacy as compared to B-LB. This study will also assess if perineur... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: Yale New Haven Hospital Saint Raphael Campus, New Haven, Connecticut
Conditions: Total Knee Replacement, Knee Arthroplasty
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Recruiting
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations
Recruiting
In this study, the investigators will recruit a cohort of elderly Black and Hispanic patients with heart failure to define the number of patients who have cardiac amyloidosis by utilizing highly sensitive heart imaging and blood tests. The investigators will also explore differences in genetics and sex as they relate to heart failure disease progression in cardiac amyloidosis.
Gender:
All
Ages:
60 years and above
Trial Updated:
02/06/2023
Locations: Yale University/Yale New Haven Medical Center, New Haven, Connecticut
Conditions: Amyloid Cardiomyopathy, Transthyretin-Related
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
Recruiting
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Gender:
All
Ages:
Between 0 days and 17 years
Trial Updated:
02/06/2023
Locations: Connecticut Children's Medical Center Pharmacy, Hartford, Connecticut
Conditions: Venous Thromboembolism
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Recruiting
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Gender:
All
Ages:
20 years and below
Trial Updated:
01/30/2023
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Recruiting
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2023
Locations: Norwalk Hospital, Norwalk, Connecticut
Conditions: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Recruiting
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis [UC]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/09/2023
Locations: Yale University, New Haven, Connecticut
Conditions: Ulcerative Colitis, Crohn Disease
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Recruiting
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth. In this study researchers want to find out whether so called gadolinium-based contrast agents (G... Read More
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
01/08/2023
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Motor Function, Cognitive Function, Contrast Media
Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
Recruiting
There is established evidence that patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Imipenem/cilastatin/relebactam is a novel broad spectrum intravenous beta-lactam/beta-lactamase inhibitor combination antibiotic with potent activity against multidrug resistant Gram-negative bacteria, including imipenem non-susceptible Pseudomonas aeruginosa. Relebactam has also been shown to restore imipenem activity in Burkholderia cepacia complex,... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
01/03/2023
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Acquiring and Targeting Heat Exposures Necessary for Action
Recruiting
The purpose of this research study is to better understand ways that women and men differ physiologically, cognitively, physically, and cellularly to better prescribe helpful interventions that will prevent injury and risk of conditions like exertional heat illnesses or heatstroke. The main questions this project aims to answer are: What is the relative stress contributing to performance differences between women and men during intense exercise in extremely hot and humid environments in respons... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
12/28/2022
Locations: Human Performance Laboratory at the University of Connecticut, Storrs, Connecticut
Conditions: Heat Intolerance, Heat Stress, Fatigue; Heat
Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
Recruiting
There is established evidence that adult patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Cefiderocol is a newly approved broad spectrum intravenous siderophore cephalosporin antibiotic, which has potent in vitro activity against multidrug resistant Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter species, and Stenotrophomonas maltophilia, all pathogens implicated in CF pulmonary exacerbations. This study will deter... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2022
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Cystic Fibrosis, Pneumonia, Bacterial